||This article does not cite any references or sources. (December 2009)|
|Systematic (IUPAC) name|
|Legal status||Prescription Only (S4) (AU) POM (UK) ℞-only (US) ℞ Prescription only|
|Routes||Subdermal as slow-release implant|
|Metabolism||Hepatic (P450 3A4)|
|Excretion||Urinary (majority) and fecal|
|Mol. mass||324.457 g/mol|
|(what is this?)|
Etonogestrel is a steroidal progestin used in hormonal contraceptives, most notably the subdermal implant Nexplanon and the vaginal ring NuvaRing.
Etonogestrel is the active metabolite of the inactive prodrug desogestrel, one of two third-generation progestins found in some epidemiological studies of combined oral contraceptive pills to be associated with a higher risk of venous thrombosis than combined oral contraceptive pills containing certain second-generation progestins. Because hormones are released continuously from NuvaRing, peak and total estrogen and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of blood clots.